3,4-Dihydroxybenzoic Acid

Identification

Generic Name
3,4-Dihydroxybenzoic Acid
DrugBank Accession Number
DB03946
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 154.1201
Monoisotopic: 154.02660868
Chemical Formula
C7H6O4
Synonyms
Not Available
External IDs
  • NSC-16631

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 3,4-Dihydroxybenzoic Acid.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with 3,4-Dihydroxybenzoic Acid.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 3,4-Dihydroxybenzoic Acid.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with 3,4-Dihydroxybenzoic Acid.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hydroxybenzoic acid derivatives. These are compounds containing a hydroxybenzoic acid (or a derivative), which is a benzene ring bearing a carboxyl and a hydroxyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Hydroxybenzoic acid derivatives
Alternative Parents
Benzoic acids / Catechols / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carboxylic acid / Carboxylic acid derivative / Catechol / Dihydroxybenzoic acid / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
catechols, dihydroxybenzoic acid (CHEBI:36062)
Affected organisms
Not Available

Chemical Identifiers

UNII
36R5QJ8L4B
CAS number
99-50-3
InChI Key
YQUVCSBJEUQKSH-UHFFFAOYSA-N
InChI
InChI=1S/C7H6O4/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,8-9H,(H,10,11)
IUPAC Name
3,4-dihydroxybenzoic acid
SMILES
OC(=O)C1=CC=C(O)C(O)=C1

References

General References
Not Available
Human Metabolome Database
HMDB0001856
KEGG Compound
C00230
PubChem Compound
72
PubChem Substance
46505638
ChemSpider
71
BindingDB
50100861
ChEBI
36062
ChEMBL
CHEMBL37537
ZINC
ZINC000000013246
PDBe Ligand
DHB
PDB Entries
1b4u / 1eob / 1n8q / 1phh / 1ykl / 1ykn / 1ykp / 2bsl / 2buv / 2bv0
show 19 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)221 dec °CPhysProp
water solubility1.82E+004 mg/L (at 14 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.86HANSCH,C ET AL. (1995)
pKa4.26 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility12.4 mg/mLALOGPS
logP1.32ALOGPS
logP1.02ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)4.16ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.76 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity37.28 m3·mol-1ChemAxon
Polarizability13.85 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8811
Blood Brain Barrier-0.6376
Caco-2 permeable+0.5553
P-glycoprotein substrateNon-substrate0.6756
P-glycoprotein inhibitor INon-inhibitor0.9829
P-glycoprotein inhibitor IINon-inhibitor0.9948
Renal organic cation transporterNon-inhibitor0.9377
CYP450 2C9 substrateNon-substrate0.8227
CYP450 2D6 substrateNon-substrate0.9151
CYP450 3A4 substrateNon-substrate0.7227
CYP450 1A2 substrateNon-inhibitor0.9545
CYP450 2C9 inhibitorNon-inhibitor0.9568
CYP450 2D6 inhibitorNon-inhibitor0.9636
CYP450 2C19 inhibitorNon-inhibitor0.9707
CYP450 3A4 inhibitorNon-inhibitor0.9535
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9564
Ames testNon AMES toxic0.9326
CarcinogenicityNon-carcinogens0.9154
BiodegradationReady biodegradable0.8871
Rat acute toxicity1.6414 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Non-inhibitor0.9508
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-0006-0913000000-0933eeed3701393aa41f
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0006-0911000000-ca1452bfe34749c0d8c1
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-00dl-9711000000-595a58baf84bb73670ae
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0006-4912000000-a095cbdb4d3809a9b775
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0gb9-9800000000-f08a8e55f19d388091c0
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0006-0913000000-0933eeed3701393aa41f
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0006-0911000000-ca1452bfe34749c0d8c1
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00dl-9711000000-595a58baf84bb73670ae
GC-MS Spectrum - GC-MSGC-MSsplash10-0006-4912000000-a095cbdb4d3809a9b775
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0006-0911000000-c141d09a094e57440cd4
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-03di-0900000000-9e8a76eec66c42952ee9
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-0296-9100000000-145f71b183841a31fdc8
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-014i-9000000000-9044e5839d8d0b8f8ee6
MS/MS Spectrum - EI-B (HITACHI M-52) , PositiveLC-MS/MSsplash10-0gb9-9800000000-f08a8e55f19d388091c0
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-0a4i-0900000000-58c9b8232fbc187217d4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4r-0900000000-99ac3661fc7809f28796
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4r-0900000000-df55ffdd340947acfac9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pc9-9500000000-201668ae66ab0379946f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4r-0900000000-99ac3661fc7809f28796
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4r-0900000000-df55ffdd340947acfac9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pc9-9500000000-201668ae66ab0379946f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-0595d63853a488b9c6cf
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pb9-0900000000-d794b62eb087aaa84f94
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9700000000-32a6fa42639cb300cdc9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-0595d63853a488b9c6cf
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pb9-0900000000-d794b62eb087aaa84f94
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9700000000-32a6fa42639cb300cdc9
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0900000000-58c9b8232fbc187217d4
MS/MS Spectrum - , negativeLC-MS/MSsplash10-0a4i-0900000000-43a650326b83e2dfe589
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0900000000-61ebd9558aeeb60dda89
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Drug created on June 13, 2005 13:24 / Updated on June 12, 2020 16:52